Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme
Metrics: PDF 1841 views | HTML 2082 views | ?
Anna Laurenzana1, Alessio Biagioni1, Silvia D’Alessio2, Francesca Bianchini1, Anastasia Chillà1, Francesca Margheri1, Cristina Luciani1, Benedetta Mazzanti3, Nicola Pimpinelli4, Eugenio Torre1, Silvio Danese2, Lido Calorini1, Mario Del Rosso1,5 and Gabriella Fibbi1,5
1 Department of Experimental and Clinical Biomedical Science, University of Florence, Italy
2 IBD Center, Humanitas Clinical and Research Center Rozzano (Mi), Italy
3 Cord Blood Bank, Careggi University Hospital, Florence, Italy
4 Clinical, Preventive and Oncologic Dermatology Section, Department of Surgery and Translational Medicine, University of Florence, Italy
5 ITT, Istituto Toscano Tumori
Gabriella Fibbi, email:
Mario Del Rosso, email:
Keywords: uPAR, MMP12, Endothelial Progenitor Cells, melanoma, cell-therapy
Received: April 1, 2014 Accepted: May 17, 2014 Published: May 19, 2014
The receptor for the urokinase-type plasminogen activator (uPAR) accounts for many features of cancer progression, and is therefore considered a target for anti-tumoral therapy. Only full length uPAR mediates tumor progression. Matrix-metallo-proteinase-12 (MMP12)-dependent uPAR cleavage results into the loss of invasion properties and angiogenesis. MMP12 can be employed in the field of “targeted therapies” as a biological drug to be delivered directly in patient’s tumor mass. Endothelial Progenitor Cells (EPCs) are selectively recruited within the tumor and could be used as cellular vehicles for delivering anti-cancer molecules. The aim of our study is to inhibit cancer progression by engeneering ECFCs, a subset of EPC, with a lentivirus encoding the anti-tumor uPAR-degrading enzyme MMP12. Ex vivo manipulated ECFCs lost the capacity to perform capillary morphogenesis and acquired the anti-tumor and anti-angiogenetic activity. In vivo MMP12-engineered ECFCs cleaved uPAR within the tumor mass and strongly inhibited tumor growth, tumor angiogenesis and development of lung metastasis.
The possibility to exploit tumor homing and activity of autologous MMP12-engineered ECFCs represents a novel way to combat melanoma by a “personalized therapy”, without rejection risk.
The i.v. injection of radiolabelled MMP12-ECFCs can thus provide a new theranostic approach to control melanoma progression and metastasis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.